High frequency of isavuconazole use over voriconazole for chronic pulmonary aspergillosis: a retrospective observational study on tolerability and therapeutic drug monitoring. (PubMed, Antimicrob Agents Chemother) - Sep 17, 2026 - "Isavuconazole demonstrated a favorable tolerability profile with no treatment discontinuations due to adverse events. Proactive TDM proved clinically valuable in guiding dose optimization and reducing drug costs, supporting isavuconazole as a viable alternative for long-term CPA management."
Journal • Observational data • Retrospective data • Infectious Disease • Pulmonary Disease • Respiratory Diseases
|
|
Agostino Riva; Alessandro Torre; Andrea Gori; Aurora Civati; Claudia Conflitti; Dario Cattaneo; Debora Visigalli; Federico Famà; Marco Schiuma; Maria Vittoria Cossu; Marta Colaneri; Silvia Borghetti; Spinello Antinori; Stefania Vimercati
|